Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (9): 537-543.doi: 10.3760/cma.j.cn371439-20201217-00104
• Original Articles • Previous Articles Next Articles
Wang Jun1(), Zhao Xia2, Li Haifei3, Zhang Cheng1
Received:
2020-12-17
Revised:
2021-01-28
Online:
2021-09-08
Published:
2021-09-22
Contact:
Wang Jun
E-mail:wjzxyjr@sina.com
Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng. Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype[J]. Journal of International Oncology, 2021, 48(9): 537-543.
"
项目 | AAH+AIS(n=16) | MIA(n=35) | IAC(n=103) | VIAC(n=6) | χ2值 | P值 |
---|---|---|---|---|---|---|
性别 | ||||||
男 | 3(6.00) | 8(16.00) | 37(74.00) | 2(4.00) | 3.370 | 0.338 |
女 | 13(11.82) | 27(24.55) | 66(60.00) | 4(3.64) | ||
结节类型 | 56.385 | <0.001 | ||||
实性结节 | 0(0) | 1(2.86) | 36(34.95) | 6(100.00) | 43.850 | <0.001 |
混合性结节 | 1(6.25) | 6(17.14) | 28(27.18) | 0(0) | 6.123 | 0.106 |
纯磨玻璃样结节 | 15(93.75) | 28(80.00) | 39(37.87) | 0(0) | 42.538 | <0.001 |
"
影像学特征 | AAH+AIS(n=16) | MIA(n=35) | IAC(n=103) | VIAC(n=6) | H/χ2值 | P值 |
---|---|---|---|---|---|---|
病灶最大径(mm) | 6.85(3.73) | 8.00(5.00) | 16.00(11.90) | 17.20(9.08) | 55.107 | <0.001 |
CT值(HU) | -563.50(176.63) | -536.00(293.50) | -235.50(346.50) | -23.00(30.50) | 47.499 | <0.001 |
结节实性占比(%) | 0(0) | 0(0) | 49.00(100.00) | 100.00(0) | 44.242 | <0.001 |
空泡征 | 14(87.50) | 35(100.00) | 84(81.55) | 3(50.00) | 13.925 | 0.002 |
充气支气管征 | 1(6.25) | 2(5.71) | 36(34.95) | 2(33.33) | 16.578 | 0.001 |
肿瘤内血管征 | 13(81.25) | 28(80.00) | 64(62.14) | 1(16.67) | 11.168 | 0.009 |
瘤肺界面(模糊) | 8(50.00) | 14(40.00) | 65(63.11) | 3(50.00) | 6.146 | 0.099 |
血管集束征 | 1(6.25) | 3(8.57) | 66(64.08) | 6(100.00) | 54.232 | <0.001 |
短毛刺征 | 3(18.75) | 11(31.43) | 77(74.76) | 6(100.00) | 36.218 | <0.001 |
分叶征 | 4(25.00) | 18(51.43) | 93(90.29) | 6(100.00) | 43.302 | <0.001 |
胸膜牵拉征 | 0(0) | 6(17.14) | 70(67.96) | 5(83.33) | 50.794 | <0.001 |
"
变量 | β值 | OR值 | 95%CI | P值 |
---|---|---|---|---|
病灶最大径 | -0.042 | 0.959 | 0.798~1.151 | 0.652 |
CT值 | -0.001 | 0.999 | 0.993~1.005 | 0.650 |
结节实性占比 | -0.018 | 0.982 | 0.932~1.034 | 0.485 |
空泡征 | 1.647 | 5.190 | 0.345~77.984 | 0.234 |
充气支气管征 | -0.508 | 0.602 | 0.035~10.267 | 0.726 |
肿瘤内血管征 | -0.203 | 0.816 | 0.141~4.711 | 0.820 |
血管集束征 | -0.644 | 0.525 | 0.027~10.324 | 0.672 |
短毛刺征 | -0.486 | 0.615 | 0.093~4.074 | 0.614 |
分叶征 | -0.887 | 0.412 | 0.084~2.010 | 0.273 |
胸膜牵拉征 | -18.593 | 0 | 0 | 0.997 |
"
变量 | β值 | OR值 | 95%CI | P值 |
---|---|---|---|---|
病灶最大径 | -0.153 | 0.858 | 0.754~0.977 | 0.021 |
CT值 | 0 | 1.000 | 0.995~1.004 | 0.890 |
结节实性占比 | -0.001 | 0.999 | 0.973~1.026 | 0.963 |
空泡征 | -19.193 | 0 | 0 | 0.998 |
充气支气管征 | 0.020 | 1.020 | 0.161~6.471 | 0.983 |
肿瘤内血管征 | 0.074 | 1.077 | 0.293~3.963 | 0.911 |
血管集束征 | -1.462 | 0.232 | 0.037~1.466 | 0.120 |
短毛刺征 | -0.128 | 0.880 | 0.248~ 3.124 | 0.843 |
分叶征 | 0.459 | 1.583 | 0.476~5.261 | 0.454 |
胸膜牵拉征 | -1.244 | 0.288 | 0.084~0.993 | 0.049 |
"
变量 | β值 | OR值 | 95%CI | P值 |
---|---|---|---|---|
病灶最大径 | 0.123 | 1.131 | 1.030~1.241 | 0.010 |
CT值 | 0.001 | 1.001 | 0.996~1.005 | 0.728 |
结节实性占比 | -0.004 | 0.996 | 0.975~1.018 | 0.727 |
空泡征 | -0.270 | 0.763 | 0.163~3.565 | 0.731 |
充气支气管征 | -0.171 | 0.843 | 0.227~3.135 | 0.799 |
肿瘤内血管征 | 0.157 | 1.170 | 0.344~3.974 | 0.801 |
血管集束征 | 0.928 | 2.529 | 0.688~9.296 | 0.162 |
短毛刺征 | 0.409 | 1.506 | 0.484~4.682 | 0.480 |
分叶征 | 0.702 | 2.018 | 0.648~6.283 | 0.226 |
胸膜牵拉征 | 1.234 | 3.441 | 1.279~9.254 | 0.014 |
"
变量 | β值 | OR值 | 95%CI | P值 | |
---|---|---|---|---|---|
病灶最大径 | -0.047 | 0.954 | 0.826~1.103 | 0.525 | |
CT值 | 0.013 | 1.013 | 0.988~1.039 | 0.307 | |
结节实性占比 | 0.000 | 1 | 0.961~1.040 | 1.000 | |
空泡征 | -0.138 | 0.871 | 0.074~10.265 | 0.913 | |
充气支气管征 | 1.217 | 3.378 | 0.356~32.070 | 0.289 | |
肿瘤内血管征 | -0.009 | 0.991 | 0.076~12.929 | 0.995 | |
血管集束征 | 13.122 | 499 735.300 | 0.000 | 0.996 | |
短毛刺征 | 14.219 | 1 497 307.819 | 0.000 | 0.996 | |
分叶征 | 16.295 | 11 934 542.510 | 0.000 | 0.997 | |
胸膜牵拉征 | 0.835 | 2.306 | 0.172~30.937 | 0.528 |
[1] |
National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low- dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5):395-409. DOI: 10.1056/NEJMoa1102873.
doi: 10.1056/NEJMoa1102873 |
[2] |
Inertnational Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, et al. Survival of patients with stage Ⅰ lung cancer detected on CT screening[J]. N Engl J Med, 2006, 355(17):1763-1671. DOI: 10.1056/NEJMoa060476.
doi: 10.1056/NEJMoa060476 |
[3] |
Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011, 6(2):244-285. DOI: 10.1097/JTO.0b03e318206a221.
doi: 10.1097/JTO.0b03e318206a221 |
[4] |
陈琦, 朱全新, 郁义星, 等. 肺部单发微小磨玻璃结节(<10 mm)MSCT特征对肺腺癌病理亚型的诊断价值[J]. 放射学实践, 2019, 34(7):778-783. DOI: 10.13609/j.cnki.1000-0313.2019.07.012.
doi: 10.13609/j.cnki.1000-0313.2019.07.012 |
[5] |
沙雪, 巩贯忠, 邓红彬, 等. 18F-FDP PET/CT影像组学预测非小细胞肺癌亚型的研究[J]. 中国医学物理学杂志, 2019, 36(3):311-315. DOI: 10.3969/j.issn.1005.202X.2019.03.013.
doi: 10.3969/j.issn.1005.202X.2019.03.013 |
[6] |
Bahleda R, Hollebecque A, Varga A, et al. PhaseⅠstudy of afatinib combined with nintedanib in patients with advanced solid tumours[J]. Br J Cancer, 2015, 113(10):1413-1420. DOI: 10.1038/bjc.2015.374.
doi: 10.1038/bjc.2015.374 |
[7] |
Wu W, Parmar C, Grossmann P, et al. Exploratory study to identify radiomics classifiers for lung cancer histology[J]. Front Oncol, 2016, 6:71. DOI: 10.3389/fonc.2016.00071.
doi: 10.3389/fonc.2016.00071 |
[8] |
Lee HY, Choi YL, Lee KS, et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management[J]. AJR Am J Roentgenol, 2014, 202(3):W224-W233. DOI: 10.2214/AJR.13.11819.
doi: 10.2214/AJR.13.11819 |
[9] |
Li Q, Fan L, Cao ET, et al. Qantitative CT analysis of pulmonary pure ground-glass nodule predicts histological invasiveness[J]. Eur J Radiol, 2017, 89:67-71. DOI: 10.1016/j.ejrad.2017.01.024.
doi: 10.1016/j.ejrad.2017.01.024 |
[10] |
Fan L, Liu SY, Li QC, et al. Multidetector CT features of pulmonary focal ground-glass opacity: differences between benign and maligant[J]. Br J Radiol, 2012, 85(1015):897-904. DOI: 10.1259/bjr/33150223.
doi: 10.1259/bjr/33150223 pmid: 22128130 |
[11] |
Lee SM, Park CM, Goo JM, et al. Invasive pulmonary adenocarcinomas versus preinvasive lesions appearing as ground-glass nodules: differentiation by using CT features[J]. Radiology, 2013, 268(1):265-273. DOI: 10.101148/radiol.13120949.
doi: 10.101148/radiol.13120949 |
[12] | 李雪梅, 武刚. 肺局灶性磨玻璃结节的高分辨CT表现与病理对照分析[J]. 哈尔滨医科大学学报, 2016, 50(1):67-70. |
[13] |
Si MJ, Tao XF, Du GY, et al. Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity[J]. Eur J Radiol, 2016, 85(10):1708-1715. DOI: 10.1016/j.ejrad.2016.07.012.
doi: 10.1016/j.ejrad.2016.07.012 |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36. |
[3] | Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716. |
[4] | Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[5] | Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660. |
[6] | Xie Yu, Zheng Shengnan, Huang Mingmin, Guo Aibin, Yin Zhenyu, Lin Yongjuan. Pemetrexed clinical trial for intrathecal injection chemotherapy based on cerebrospinal fluid pharmacokinetics in patients with leptomeningeal metastasis from lung adenocarcinoma [J]. Journal of International Oncology, 2023, 50(10): 585-591. |
[7] | Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536. |
[8] | Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463. |
[9] | Lin Yongjuan, Li Huiying, Yin Zhenyu, Guo Aibin, Xie Yu. Investigation of cerebrospinal fluid metabolites in patients with leptomeningeal metastases from lung adenocarcinoma based on untargeted metabolomics [J]. Journal of International Oncology, 2022, 49(7): 390-399. |
[10] | Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370. |
[11] | Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301. |
[12] | Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251. |
[13] | Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145. |
[14] | Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115. |
[15] | Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||